Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The novel drug candidate VOMG kills Mycobacterium abscessus and other pathogens by inhibiting cell division

27 Jul 2024

Abstract excerpt

AIMS: The incidence of lung infections is increasing worldwide in individuals suffering from cystic fibrosis and chronic obstructive pulmonary disease. Mycobacterium abscessus is associated with chronic lung deterioration in these populations. The intrinsic resistance of M. abscessus to most conventional antibiotics jeopardizes treatment success rates. To date, no single drug has been developed targeting M....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Infectious Diseases and Tuberculosis
Share to Mycobacterium research and diagnosis
Share to Tuberculosis Research and Epidemiology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39069229
DOI: 10.1016/j.ijantimicag.2024.107278

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The novel drug candidate VOMG kills Mycobacterium abscessus and other pathogens by inhibiting cell divisionPMID 39069229Read ↗

Pathogen Box screening for hit identification against Mycobacterium abscessusSemantic proximity Read ↗

Pipeline of anti‐Mycobacterium abscessussmall molecules: Repurposable drugs and promising novel chemical entitiesSemantic proximity Read ↗

Rifabutin Is Active against Mycobacterium abscessus ComplexSemantic proximity Read ↗

Pharmacological validation of dihydrofolate reductase as a drug target in Mycobacterium abscessusSemantic proximity Read ↗

Resistance to Thiacetazone Derivatives Active against Mycobacterium abscessus Involves Mutations in the MmpL5 Transcriptional Repressor MAB_4384.Semantic proximity Read ↗

Activity of LCB01-0371, a Novel Oxazolidinone, against Mycobacterium abscessusSemantic proximity Read ↗

Bedaquiline Inhibits the ATP Synthase in Mycobacterium abscessus and Is Effective in Infected Zebrafish.Semantic proximity Read ↗

The Repurposing of FDA-Approved Drugs as FtsZ Inhibitors against Mycobacterium tuberculosis: An In Silico and In Vitro StudySemantic proximity Read ↗

Mycobacterium abscessus: a new antibiotic nightmareSemantic proximity Read ↗

Identification of a New FtsZ Inhibitor by Virtual Screening, Mechanistic Insights, and Structure–Activity Relationship AnalysesSemantic proximity Read ↗

REBASTINIB, OLVEREMBATINIB, AND NAS-181 INHIBIT <i>MYCOBACTERIUM ABSCESSUS</i> BY DISRUPTING MYCOTHIOL HOMEOSTASISSemantic proximity Read ↗

Exploring the Role of Berberine as a Molecular Disruptor in Antimicrobial StrategiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.